Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$1.4 million.

  • Taysha Gene Therapies' Change in Accured Expenses rose 1070.09% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 204.99%. This contributed to the annual value of -$1.4 million for FY2024, which is 77.36% up from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Change in Accured Expenses is -$1.4 million, which was up 77.36% from -$6.3 million recorded in FY2023.
  • Taysha Gene Therapies' Change in Accured Expenses' 5-year high stood at $17.5 million during FY2021, with a 5-year trough of -$9.3 million in FY2022.
  • For the 3-year period, Taysha Gene Therapies' Change in Accured Expenses averaged around -$5.7 million, with its median value being -$6.3 million (2023).
  • Per our database at Business Quant, Taysha Gene Therapies' Change in Accured Expenses surged by 288.79% in 2021 and then crashed by 153.15% in 2022.
  • Taysha Gene Therapies' Change in Accured Expenses (Yearly) stood at $4.5 million in 2020, then spiked by 288.79% to $17.5 million in 2021, then crashed by 153.15% to -$9.3 million in 2022, then surged by 32.67% to -$6.3 million in 2023, then skyrocketed by 77.36% to -$1.4 million in 2024.